Cantor Fitzgerald Reaffirms “Overweight” Rating for Zevra Therapeutics (NASDAQ:ZVRA)

Cantor Fitzgerald reiterated their overweight rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research note released on Wednesday morning, Benzinga reports.

Separately, HC Wainwright lifted their price objective on Zevra Therapeutics from $15.00 to $18.00 and gave the stock a buy rating in a report on Monday, August 5th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $20.25.

Zevra Therapeutics Stock Up 3.4 %

ZVRA opened at $7.37 on Wednesday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.10 and a quick ratio of 2.10. The business has a 50 day simple moving average of $5.69 and a 200-day simple moving average of $5.52. The stock has a market capitalization of $308.46 million, a P/E ratio of -5.46 and a beta of 1.97. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $8.44.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The business had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. During the same period in the prior year, the business earned ($0.15) earnings per share. On average, equities analysts anticipate that Zevra Therapeutics will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Thomas Anderson purchased 10,000 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was bought at an average price of $6.81 per share, with a total value of $68,100.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at approximately $136,200. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders bought 22,000 shares of company stock valued at $140,340. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently bought and sold shares of ZVRA. International Assets Investment Management LLC increased its position in Zevra Therapeutics by 555.0% during the fourth quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock worth $43,000 after buying an additional 5,550 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics during the first quarter worth $64,000. The Manufacturers Life Insurance Company increased its position in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after buying an additional 2,452 shares in the last quarter. IFG Advisors LLC increased its position in Zevra Therapeutics by 45.0% during the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after buying an additional 5,800 shares in the last quarter. Finally, Strs Ohio increased its position in Zevra Therapeutics by 151.9% during the fourth quarter. Strs Ohio now owns 19,400 shares of the company’s stock worth $127,000 after buying an additional 11,700 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.